Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and hyaluronic acid (HA) manufacturing. This Form 10-Q covers the quarterly period ended June 30, 2026. The Company recently transitioned from a fiscal year ending the last Sunday of May to a calendar year ending December 31, effective August 1, 2025. Consequently, comparative data is presented for the three and six months ended May 25, 2025.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $34,167 | $57,360 |
| Gross Profit | $12,075 | $16,537 |
| Gross Margin | 35.3% | 28.8% |
| Operating Loss | $(2,105) | $(2,105) |
| Net Loss | $(6,156) | $(21,136) |
| Loss Per Share (Basic & Diluted) | $(0.19) | $(0.61) |
| Cash and Cash Equivalents | $17,241 | $17,241 |
| Net Cash Provided by Operating Activities | N/A | $2,511 |
| Total Debt (Principal) | $203,922 | $203,922 |
| Consolidated Liquidity | $38.8M (Cash + Revolver Availability) | $38.8M |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 6% ($2.3M) for the quarter and 20% ($14.2M) for the six months compared to the prior period. This was driven primarily by a significant drop in CDMO revenue due to lower sales volumes and the completion of discrete development projects in the prior year. HA manufacturing revenue increased 44% in the quarter but declined 5% for the six months.
- Margin Compression: Gross profit margins declined to 35.3% (Q2) and 28.8% (YTD) from 38.4% and 33.3% respectively in the prior year, attributed to unfavorable net realizable value adjustments and manufacturing variances in the CDMO segment.
- Expense Reductions: Operating expenses decreased significantly. SG&A expenses fell 11% ($1.0M) for the quarter and 17% ($3.2M) for the six months, driven by lower legal/accounting fees and reduced non-recurring costs. R&D expenses also declined due to headcount reductions and increased utilization of personnel on revenue-generating projects.
- Interest Expense Surge: Net interest expense increased 38% ($2.1M) for the quarter and 35% ($3.8M) for the six months. This is primarily due to the accumulation of interest paid-in-kind (PIK) on the related-party term loan with Alcon and the amortization of debt discounts.
- Debt Derivative Liability: The change in fair value of the debt derivative liability resulted in a non-operating loss of $1.2M for the quarter and $4.4M for the six months, an increase from the prior year due to changes in valuation inputs and discount rates.
Outlook, Risks, and Contingencies
- Preferred Stock Redemption: Holders of Series A Redeemable Convertible Preferred Stock have exercised their right to redeem all 49,263 shares. The redemption date is December 28, 2026, with a total obligation of approximately $50.2 million (including accrued dividends). The Company currently lacks sufficient cash to fund this redemption and must obtain lender waivers or pursue strategic alternatives (equity/debt financing) to avoid a breach of credit agreements.
- Liquidity Position: As of June 30, 2026, the Company had $17.2 million in cash and $21.6 million available under its Revolving Credit Facility. It remains in compliance with its minimum liquidity covenant of $4.0 million.
- Legal Proceedings:
- Class Action: A proposed settlement regarding a securities class action was preliminarily approved by the court in March 2026, with final approval pending. The Company expects this to be covered by insurance with no material loss.
- Investor Dispute: A lawsuit by 22NW Fund regarding registration delay fees and misrepresentations is ongoing. Most claims were dismissed, but the Company intends to defend against remaining claims regarding express representations.
- Yucatan Litigation: Ongoing litigation regarding the 2018 acquisition of Yucatan Foods involves multiple defendants and appeals. The outcome remains uncertain.
- Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting related to its legacy ERP system. While a new ERP system was launched in January 2026, the weakness has not yet been fully remediated as of June 30, 2026.
Investor Verification Checklist
- Preferred Stock Redemption Plan: Verify the Company's specific strategy and timeline for raising the ~$50 million required to redeem the Series A Preferred Stock by December 2026.
- Alcon Dependency: Confirm the stability of the relationship with Alcon, which represents 55% of revenue and is the primary lender (related party debt of ~$193M).
- Interest Rate Impact: Assess the long-term impact of the 20.9% effective interest rate on the term loan and the compounding effect of interest paid-in-kind on future debt principal.
- ERP Remediation: Monitor the progress of the new ERP system implementation and the timeline for closing the material weakness in internal controls.
- CDMO Pipeline: Evaluate the pipeline of new development projects to offset the decline in CDMO revenue caused by the completion of prior projects.